GLP-1R agonists were initially used to treat T2DM and soon after it was found that these drugs possess many other physiological properties, such as neuroprotection, neurotrophic, and anti-inflammatory effects, which may be useful to slow the progression of AD (Figure 3) (17). The gene discussed is GLP1R; the disease is Alzheimer disease.